Polymorphisms, hypertension and thiazide diuretics

Lorena Citterio, Chiara Lanzani, Paolo Manunta

Research output: Contribution to journalArticle

Abstract

It is 10 years since the discovery of the human genome; however, the study of the influence of genetic variants on drug effect - pharmacogenomics - has so far failed to create a major impact on day-to-day prescription practices. In the present article we analyze the main findings in candidate gene variants, gene combinations and whole-genome scans in relation to diuretic treatment. A critical analysis of the main reasons for some contrasting results will be discussed. The hypertension phases, in clinical trials dealing with genes and related pathophysiological mechanisms, may account for these inconsistent findings. The use of previously untreated versus treated patients is addressed. Finally, a positive study with a new genetic molecular strategy is described.

Original languageEnglish
Pages (from-to)1587-1604
Number of pages18
JournalPharmacogenomics
Volume12
Issue number11
DOIs
Publication statusPublished - Nov 2011

Keywords

  • drugs
  • genes
  • hypertension
  • personalized medicine
  • sodium pump inhibitor
  • therapy

ASJC Scopus subject areas

  • Pharmacology
  • Genetics
  • Molecular Medicine

Fingerprint Dive into the research topics of 'Polymorphisms, hypertension and thiazide diuretics'. Together they form a unique fingerprint.

Cite this